Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Nasdaq

Mid-Morning Market Update: Markets Open Lower; U.S. Producer Prices Rise 0.5% In April

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 200 points on Thursday.

Benzinga

Looking Into Huron Consulting Group's Return On Invested Capital

According to Benzinga Pro data Huron Consulting Group (NASDAQ:HURN) posted a 13.54% decrease in earnings from Q4. Sales, however, increased by 4.73% over the previous quarter to $260.05 million.

Benzinga

Verisk Analytics's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, Verisk Analytics (NASDAQ:VRSK) earned $505.80 million, a 256.7% increase from the preceding quarter. Verisk Analytics also posted a total of $775.50 million in sales, a 1.24% increase since Q4.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Denny's's Return on Invested Capital Insights

Pulled from Benzinga Pro data, Denny's (NASDAQ:DENN) posted Q1 earnings of $21.86 million, an increase from Q4 of 49.71%. Sales dropped to $103.11 million, a 4.21% decrease between quarters.

Benzinga

Looking Into Infinera's Return On Capital Employed

Infinera (NASDAQ:INFN) brought in sales totaling $338.87 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 26.56%, resulting in a loss of $41.85 million.

Benzinga

Apollo Endosurgery's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Apollo Endosurgery's (NASDAQ:APEN) reported sales totaled $16.66 million. Despite a 19.14% increase in earnings, the company posted a loss of $8.41 million.

Benzinga

CytoSorbents's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in earnings, the company posted a loss of $8.97 million.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What 4 Analyst Ratings Have To Say About Enanta Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Enanta Pharmaceuticals (NASDAQ:ENTA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Peering Into Coinbase Global's Recent Short Interest

Coinbase Global's (NASDAQ:COIN) short percent of float has risen 17.45% since its last report. The company recently reported that it has 7.28 million shares sold short, which is 4.98% of all regular shares that are available for trading.

Benzinga

Data Is The New Oil? Not Yet! Saudi Aramco Surpasses Apple To Become Most Valuable Company

Saudi Aramco has beaten Apple Inc (NASDAQ: AAPL) to become the most valuable company,

Benzinga

CEO Of 'India's Robinhood' Echoes Coinbase's Warning: Crypto Exchanges Carry A Risk

Indian financial services firm Zerodha's co-founder and CEO Nithin Kamath sounded the alarm for crypto investors as the U.S. cryptocurrency exchange Coinbase Global Inc (NASDAQ: COIN) shot a bankruptcy-related warning.

Benzinga

Where Food Comes From: Q1 Earnings Insights

Where Food Comes From (NASDAQ:WFCF) reported its Q1 earnings results on Thursday, May 12, 2022 at 09:30 AM. Here's what investors need to know about the announcement.

Benzinga

4 Analysts Have This to Say About Atlantica Sustainable

Analysts have provided the following ratings for Atlantica Sustainable (NASDAQ:AY) within the last quarter:

Benzinga

RVL Pharmaceuticals: Q1 Earnings Insights

RVL Pharmaceuticals (NASDAQ:RVLP) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:50 AM. Here's what investors need to know about the announcement.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2022

Benzinga

Alibaba And Other Chinese Stock Investors Remain Cautious Over China's Political Body Forum With Leading Firms

China’s top political advisory body looks to host a forum next week with some of the nation’s largest private-sector firms, including Baidu, Inc (NASDAQ:BIDU), Bloomberg reports. While the conference focused on developing China’s digital economy, investors will likely watch for a possible wind-down of its year-long crackdown on the tech sector after a…

Benzinga

Where SciPlay Stands With Analysts

Within the last quarter, SciPlay (NASDAQ:SCPL) has observed the following analyst ratings:

Benzinga

Expert Ratings for Prelude Therapeutics

Prelude Therapeutics (NASDAQ:PRLD) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Carrols Restaurant Reports Mixed Q1 Results

Carrols Restaurant Group Inc (NASDAQ:TAST) reported first-quarter FY22 sales growth of 2.4% year-on-year to $399.48 million, missing the consensus of $402.37 million. Comparable restaurant sales for Burger King restaurants increased 1.6%, and Popeyes restaurants increased 2.2%. Operating expenses rose 6.7% Y/Y to $419.3 million. The operating loss for the quarter was $(19.8) million…

Benzinga

Rivian Sees Price Target Halved At Wedbush: Analyst Sees Potential But It's Time To 'Stop The Excuses'

Rivian Automotive Inc (NASDAQ: RIVN) has the potential to be a major electric vehicle stalwart over the next decade but it needs to start delivering models and "stop the excuses" to reach that goal, Wedbush analyst Dan Ives said on Wednesday as he

Benzinga

Recap: Aptevo Therapeutics Q1 Earnings

Aptevo Therapeutics (NASDAQ:APVO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

MeiraGTx Hldgs: Q1 Earnings Insights

MeiraGTx Hldgs (NASDAQ:MGTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Benzinga

Recap: Artelo Biosciences Q2 Earnings

Artelo Biosciences (NASDAQ:ARTL) reported its Q2 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Harbor Custom Dev Q1 Earnings

Harbor Custom Dev (NASDAQ:HCDI) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

1 … 523 524 525 526

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.